Stoke Therapeutics Announces $200M At‑The‑Market Offering

What Happened

• Stoke Therapeutics, Inc. filed a Current Report on Form 8‑K (Item 8.01) on August 3, 2026 announcing that it submitted a prospectus supplement under Rule 424(b) to offer and sell up to $200,000,000 of its common stock.
• The shares would be offered as “Placement Shares” under the Company’s Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., originally entered on May 20, 2022, and the prospectus supplement is part of the Company’s automatic shelf registration statement on Form S‑3ASR (filed March 18, 2026).
• The legal opinion of Fenwick & West LLP relating to the Placement Shares is filed as Exhibit 5.1 to the 8‑K.

Key Details

• Offering amount: up to $200,000,000 of common stock.
• Sales agent: Cantor Fitzgerald & Co., pursuant to the Company’s existing ATM (at‑the‑market) Sales Agreement (entered May 20, 2022).
• Prospectus supplement filed with the SEC on August 3, 2026 (Rule 424(b)), tied to Form S‑3ASR (File No. 333‑294402) filed March 18, 2026.
• Legal opinion and consent from Fenwick & West LLP included as exhibits.

Why It Matters

• This filing enables Stoke to raise capital quickly and flexibly by selling shares at prevailing market prices through Cantor Fitzgerald; such proceeds can be used for ongoing operations, R&D or other corporate purposes.
• If and when shares are sold under the ATM, existing shareholders could experience dilution because new shares would increase the total share count.
• The 8‑K and prospectus supplement authorize the potential sale but do not mean shares have been sold yet; any sales will be subject to market conditions and applicable legal restrictions.